CSL Ltd (ASX: CSL) shares have fallen around 0.5% in Wednesday morning trade, to $198.92 at the time of writing.
Despite this morning's decrease, the shares have now rebounded 116% since hitting a 10-year low in June this year.
The ASX biotech shares are now up around 16% year-to-date and 10% higher than 12 months ago.
There has been a huge rebound in investor confidence in CSL shares over the past couple of months, driven by an impressive FY26 result, news of a new exclusive deal, and the appointment of a new CEO.
It looks like the company is finally turning a corner. But now the question is, at around the $199 mark, are CSL shares still a bargain, or a risky investment?
Let's take a look.

Image source: Getty Images
The business has huge market scale
CSL has an incredibly dominant position in a high-growth global biotechnology market. As a company that develops and delivers biotherapies and vaccines to support people with life-threatening medical conditions, its products are in high demand.
The company has three major divisions. CSL's Behring is a major powerhouse in the global plasma market. Its Seqirus business is the world's second-largest influenza vaccine manufacturer. And CSL Vifor is a global leader in therapies for iron deficiency and iron deficiency anaemia.
There is also likely to be an ongoing need for immunoglobulin, influenza vaccines, and plasma therapies, and CSL is well-placed to scoop up a lot of that demand.
It's returning to growth… slowly
CSL suffered a shaky 18-month period to mid-2026, but plans to undertake aggressive cost-saving measures and a restructure have helped create a turnaround in earnings in FY26.
In FY26, the company delivered US$176 million in pre-tax savings, which was well ahead of schedule. It also reported total revenue of US$15.8 billion and underlying NPAT of US$3.1 billion for FY26 in mid-August.
Management described FY26 as a 'reset year' for CSL and said it expects FY27 to be the year the company returns to growth, with guidance of a 5% increase in underlying NPAT.
Guidance signals an operational turnaround and bottom line recovery for CSL. But a 5% NPAT increase suggests a slow return to growth, rather than an aggressive one.
It makes me question: is CSL's ability to generate growth and profit now reliant on its aggressive cost-cutting plan, or true business expansion?
Headwinds are still there
The huge operational headwinds the company has faced this year, including higher costs, logistics and shipping issues, and softer US vaccine demand, aren't likely to abate in the near term.
Brokers think CSL shares are fully priced
Analysts are mostly positive on the biotech shares going forward. But after such a huge rebound from the June low, it looks like they've reached around fair value.
TradingView data shows the majority of analysts (10 out of 19) still maintain a buy/strong buy rating. Another eight rate CSL shares as a hold, and one has a sell rating.
The average $200.57 target price implies the shares only have a small potential upside of around 1% at the time of writing.
Are CSL shares a bargain or a risk at $199? Here's my verdict
CSL has undergone an impressive operational turnaround this year. But after such a strong share price rally over the past five months, I think CSL shares could be risky.
The shares are no longer trading at a bargain price. I'm also concerned that the latest rally assumes CSL's growth plans will unfold without issues.
The risk is that any setback could significantly derail confidence and send the share price crashing.
Until I see further evidence that CSL's cost efficiency and growth plans are trickling through to its balance sheet, I'm sitting tight for now.